Head to Head Survey: STAAR Surgical (STAA) & Its Rivals
STAAR Surgical (NASDAQ: STAA) is one of 84 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its peers? We will compare STAAR Surgical to similar businesses based on the strength of its institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.
This table compares STAAR Surgical and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|STAAR Surgical Competitors||-128.72%||-37.35%||-10.53%|
Insider & Institutional Ownership
76.5% of STAAR Surgical shares are owned by institutional investors. Comparatively, 63.4% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 5.6% of STAAR Surgical shares are owned by company insiders. Comparatively, 13.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Risk and Volatility
STAAR Surgical has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Comparatively, STAAR Surgical’s peers have a beta of 1.08, indicating that their average share price is 8% more volatile than the S&P 500.
This is a breakdown of current ratings and recommmendations for STAAR Surgical and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|STAAR Surgical Competitors||322||1477||2588||105||2.55|
STAAR Surgical currently has a consensus price target of $12.00, indicating a potential upside of 7.14%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 5.11%. Given STAAR Surgical’s higher possible upside, equities analysts plainly believe STAAR Surgical is more favorable than its peers.
Earnings & Valuation
This table compares STAAR Surgical and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|STAAR Surgical||$84.48 million||-$672,999.00||-101.82|
|STAAR Surgical Competitors||$827.05 million||$159.46 million||33.79|
STAAR Surgical’s peers have higher revenue and earnings than STAAR Surgical. STAAR Surgical is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
STAAR Surgical Company Profile
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery. It makes lenses used across the world in corrective or refractive surgery, and makes lenses for use in surgery that treats cataracts. Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). As of December 30, 2016, it sold its products in more than 60 countries, with direct distribution in the United States, Canada, Japan and Spain, and independent distribution in the remainder of the world.
Receive News & Stock Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related stocks with our FREE daily email newsletter.